https://stock.noler.com/us/stock/genzyme-corp https://stock.noler.com/us/stock/genzyme-corp/accounts-payable https://stock.noler.com/us/stock/genzyme-corp/accounts-receivable https://stock.noler.com/us/stock/genzyme-corp/accretion-expense https://stock.noler.com/us/stock/genzyme-corp/accrued-income-taxes-current https://stock.noler.com/us/stock/genzyme-corp/accrued-liabilities-current https://stock.noler.com/us/stock/genzyme-corp/accrued-royalties-current https://stock.noler.com/us/stock/genzyme-corp/accumulated-depreciation https://stock.noler.com/us/stock/genzyme-corp/accumulated-oci-foreign-currency-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/genzyme-corp/acquired-indefinite-lived-intangible-asset-amount https://stock.noler.com/us/stock/genzyme-corp/acquired-net https://stock.noler.com/us/stock/genzyme-corp/acquisition-bargain-purchase-gain-recognized-amount https://stock.noler.com/us/stock/genzyme-corp/acquisitions https://stock.noler.com/us/stock/genzyme-corp/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/genzyme-corp/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/genzyme-corp/additional-paid-in-capital https://stock.noler.com/us/stock/genzyme-corp/adjustments-noncash-items-to-reconcile-net-income-loss-to-cash-provided-by-used-in-operating-activities-other https://stock.noler.com/us/stock/genzyme-corp/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/genzyme-corp/allowance-for-doubtful-accounts-receivable-current https://stock.noler.com/us/stock/genzyme-corp/amended-reports-10-k https://stock.noler.com/us/stock/genzyme-corp/amended-reports-10-q https://stock.noler.com/us/stock/genzyme-corp/amortization https://stock.noler.com/us/stock/genzyme-corp/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/genzyme-corp/aoci https://stock.noler.com/us/stock/genzyme-corp/asset-impairment-charges https://stock.noler.com/us/stock/genzyme-corp/assets-held-for-sale-current https://stock.noler.com/us/stock/genzyme-corp/assets-held-for-sale-long-lived https://stock.noler.com/us/stock/genzyme-corp/assets-of-disposal-group-including-discontinued-operation-current https://stock.noler.com/us/stock/genzyme-corp/assets-of-disposal-group-including-discontinued-operation-noncurrent https://stock.noler.com/us/stock/genzyme-corp/available-for-sale-debt-current https://stock.noler.com/us/stock/genzyme-corp/available-for-sale-debt-noncurrent https://stock.noler.com/us/stock/genzyme-corp/available-for-sale-equity-securities https://stock.noler.com/us/stock/genzyme-corp/available-for-sale-equity-securities-noncurrent https://stock.noler.com/us/stock/genzyme-corp/bank-overdrafts https://stock.noler.com/us/stock/genzyme-corp/basic-shares https://stock.noler.com/us/stock/genzyme-corp/business-acquisition-contingent-consideration-at-fair-value https://stock.noler.com/us/stock/genzyme-corp/business-acquisition-cost-of-acquired-entity-cash-paid https://stock.noler.com/us/stock/genzyme-corp/business-acquisition-purchase-price-allocation-amortizable-intangible-assets https://stock.noler.com/us/stock/genzyme-corp/business-acquisition-purchase-price-allocation-assets-acquired https://stock.noler.com/us/stock/genzyme-corp/business-acquisition-purchase-price-allocation-intangible-assets-not-amortizable https://stock.noler.com/us/stock/genzyme-corp/business-exit-costs https://stock.noler.com/us/stock/genzyme-corp/buybacks-form-sc-13e4 https://stock.noler.com/us/stock/genzyme-corp/buybacks-share-repurchases https://stock.noler.com/us/stock/genzyme-corp/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/genzyme-corp/capital-expenditures https://stock.noler.com/us/stock/genzyme-corp/capital-lease-obligations https://stock.noler.com/us/stock/genzyme-corp/capital-lease-obligations-current https://stock.noler.com/us/stock/genzyme-corp/capital-lease-obligations-noncurrent https://stock.noler.com/us/stock/genzyme-corp/capital-leases-balance-sheet-assets-by-major-class-net https://stock.noler.com/us/stock/genzyme-corp/capital-leases-future-minimum-payments-due https://stock.noler.com/us/stock/genzyme-corp/capital-leases-future-minimum-payments-due-current https://stock.noler.com/us/stock/genzyme-corp/capital-leases-future-minimum-payments-due-in-five-years https://stock.noler.com/us/stock/genzyme-corp/capital-leases-future-minimum-payments-due-in-four-years https://stock.noler.com/us/stock/genzyme-corp/capital-leases-future-minimum-payments-due-in-three-years https://stock.noler.com/us/stock/genzyme-corp/capital-leases-future-minimum-payments-due-in-two-years https://stock.noler.com/us/stock/genzyme-corp/capital-leases-future-minimum-payments-due-thereafter https://stock.noler.com/us/stock/genzyme-corp/capital-leases-future-minimum-payments-interest-included-in-payments https://stock.noler.com/us/stock/genzyme-corp/capital-leases-lessee-balance-sheet-assets-by-major-class-accumulated-deprecation https://stock.noler.com/us/stock/genzyme-corp/capital-leases-lessee-balance-sheet-assets-by-major-class-building https://stock.noler.com/us/stock/genzyme-corp/capitalized-computer-software-net https://stock.noler.com/us/stock/genzyme-corp/cash-and-equivalents https://stock.noler.com/us/stock/genzyme-corp/cash-flow-breakdown https://stock.noler.com/us/stock/genzyme-corp/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/genzyme-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/genzyme-corp/common-stock-value https://stock.noler.com/us/stock/genzyme-corp/comprehensive-income-net-of-tax-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/genzyme-corp/construction-in-progress-gross https://stock.noler.com/us/stock/genzyme-corp/convertible-notes-payable https://stock.noler.com/us/stock/genzyme-corp/cost-of-goods-sold https://stock.noler.com/us/stock/genzyme-corp/cost-of-services https://stock.noler.com/us/stock/genzyme-corp/costs-and-expenses https://stock.noler.com/us/stock/genzyme-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/genzyme-corp/cumulative-effect-of-initial-adoption-of-fin-48 https://stock.noler.com/us/stock/genzyme-corp/current-assets https://stock.noler.com/us/stock/genzyme-corp/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/genzyme-corp/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/genzyme-corp/current-income-tax-expense-benefit https://stock.noler.com/us/stock/genzyme-corp/current-liabilities https://stock.noler.com/us/stock/genzyme-corp/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/genzyme-corp/debt-and-capital-lease-obligations https://stock.noler.com/us/stock/genzyme-corp/debt-convertible-effective-interest-rate https://stock.noler.com/us/stock/genzyme-corp/debt-face-amount https://stock.noler.com/us/stock/genzyme-corp/debt-maturing-after-year-five https://stock.noler.com/us/stock/genzyme-corp/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/genzyme-corp/debt-maturing-in-year-five https://stock.noler.com/us/stock/genzyme-corp/debt-maturing-in-year-four https://stock.noler.com/us/stock/genzyme-corp/debt-maturing-in-year-three https://stock.noler.com/us/stock/genzyme-corp/debt-maturing-in-year-two https://stock.noler.com/us/stock/genzyme-corp/debt-unamortized-discount https://stock.noler.com/us/stock/genzyme-corp/deferred-compensation-arrangement-with-individual-distributions-paid https://stock.noler.com/us/stock/genzyme-corp/deferred-compensation-arrangement-with-individual-shares-authorized-for-issuance https://stock.noler.com/us/stock/genzyme-corp/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/genzyme-corp/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/genzyme-corp/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/genzyme-corp/deferred-revenue-and-credits-current https://stock.noler.com/us/stock/genzyme-corp/deferred-revenue-noncurrent https://stock.noler.com/us/stock/genzyme-corp/deferred-state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-capital-loss-carryforwards https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-inventory https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-net https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-net-current https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-net-noncurrent https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/genzyme-corp/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals https://stock.noler.com/us/stock/genzyme-corp/defined-contribution-plan-cost-recognized https://stock.noler.com/us/stock/genzyme-corp/deposits-assets-current https://stock.noler.com/us/stock/genzyme-corp/depreciation https://stock.noler.com/us/stock/genzyme-corp/depreciation-and-amortization https://stock.noler.com/us/stock/genzyme-corp/diluted-shares https://stock.noler.com/us/stock/genzyme-corp/dilutive-shares https://stock.noler.com/us/stock/genzyme-corp/discontinued-operation-income-loss-from-discontinued-operation-during-phase-out-period-before-income-tax https://stock.noler.com/us/stock/genzyme-corp/discontinued-operation-income-loss-from-discontinued-operation-during-phase-out-period-net-of-tax https://stock.noler.com/us/stock/genzyme-corp/discontinued-operation-tax-effect-of-income-loss-from-discontinued-operation-during-phase-out-period https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-accounts-notes-and-loans-receivable-net https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-accounts-payable https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-accrued-liabilities https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-cash-and-cash-equivalents https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-goodwill https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-intangible-assets-net https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-inventory https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-other-current-assets https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-other-current-liabilities https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-other-noncurrent-assets https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-other-noncurrent-liabilities https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-property-plant-and-equipment-net https://stock.noler.com/us/stock/genzyme-corp/disposal-group-including-discontinued-operation-revenue https://stock.noler.com/us/stock/genzyme-corp/effective-tax-rate https://stock.noler.com/us/stock/genzyme-corp/employee-related-liabilities-current https://stock.noler.com/us/stock/genzyme-corp/eps https://stock.noler.com/us/stock/genzyme-corp/eps-basic https://stock.noler.com/us/stock/genzyme-corp/excess-tax-benefit-from-share-based-compensation-financing-activities https://stock.noler.com/us/stock/genzyme-corp/excess-tax-benefit-from-share-based-compensation-operating-activities https://stock.noler.com/us/stock/genzyme-corp/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/genzyme-corp/fair-value-investments https://stock.noler.com/us/stock/genzyme-corp/fair-value-of-assets-acquired https://stock.noler.com/us/stock/genzyme-corp/financing-cash-flow https://stock.noler.com/us/stock/genzyme-corp/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/genzyme-corp/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/genzyme-corp/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/genzyme-corp/finite-lived-intangible-assets-useful-life-maximum https://stock.noler.com/us/stock/genzyme-corp/finite-lived-intangible-assets-useful-life-minimum https://stock.noler.com/us/stock/genzyme-corp/foreign-currency-contract-asset-fair-value-disclosure https://stock.noler.com/us/stock/genzyme-corp/foreign-currency-transaction-gain-loss-before-tax https://stock.noler.com/us/stock/genzyme-corp/foreign-pretax-income https://stock.noler.com/us/stock/genzyme-corp/furniture-and-fixtures-gross https://stock.noler.com/us/stock/genzyme-corp/future-amortization-expense-year-five https://stock.noler.com/us/stock/genzyme-corp/future-amortization-expense-year-four https://stock.noler.com/us/stock/genzyme-corp/future-amortization-expense-year-one https://stock.noler.com/us/stock/genzyme-corp/future-amortization-expense-year-three https://stock.noler.com/us/stock/genzyme-corp/future-amortization-expense-year-two https://stock.noler.com/us/stock/genzyme-corp/gain-loss-on-foreign-currency-derivatives-recorded-in-earnings-net https://stock.noler.com/us/stock/genzyme-corp/gain-loss-on-investments https://stock.noler.com/us/stock/genzyme-corp/gain-loss-on-sale-of-equity-investments https://stock.noler.com/us/stock/genzyme-corp/gain-loss-on-sale-of-equity-method-investments https://stock.noler.com/us/stock/genzyme-corp/gain-loss-on-sale-of-investments https://stock.noler.com/us/stock/genzyme-corp/gain-loss-on-sale-of-project https://stock.noler.com/us/stock/genzyme-corp/gain-on-purchase-of-business https://stock.noler.com/us/stock/genzyme-corp/geographic-long-lived-assets-in-individual-foreign-countries-amount https://stock.noler.com/us/stock/genzyme-corp/geographic-revenue-from-external-customers-attributed-to-entitys-country-of-domicile https://stock.noler.com/us/stock/genzyme-corp/goodwill https://stock.noler.com/us/stock/genzyme-corp/goodwill-impairment-loss https://stock.noler.com/us/stock/genzyme-corp/goodwill-translation-and-purchase-accounting-adjustments https://stock.noler.com/us/stock/genzyme-corp/gross-profit https://stock.noler.com/us/stock/genzyme-corp/impairment-of-long-lived-assets-to-be-disposed-of https://stock.noler.com/us/stock/genzyme-corp/income-loss-from https://stock.noler.com/us/stock/genzyme-corp/income-loss-from-discontinued-operations-net-of-tax https://stock.noler.com/us/stock/genzyme-corp/income-loss-from-discontinued-operations-net-of-tax-attributable-to-reporting-entity https://stock.noler.com/us/stock/genzyme-corp/income-loss-from-discontinued-operations-net-of-tax-per-basic-share https://stock.noler.com/us/stock/genzyme-corp/income-loss-from-discontinued-operations-net-of-tax-per-diluted-share https://stock.noler.com/us/stock/genzyme-corp/income-loss-from-equity-method-investments https://stock.noler.com/us/stock/genzyme-corp/income-loss-from-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/genzyme-corp/income-loss-from-per-basic-share https://stock.noler.com/us/stock/genzyme-corp/income-loss-from-per-diluted-share https://stock.noler.com/us/stock/genzyme-corp/income-tax https://stock.noler.com/us/stock/genzyme-corp/income-tax-examination-liability-refund-adjustment-from-settlement-with-taxing-authority https://stock.noler.com/us/stock/genzyme-corp/income-taxes-paid https://stock.noler.com/us/stock/genzyme-corp/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/genzyme-corp/increase-decrease-in-accrued-income-taxes-payable https://stock.noler.com/us/stock/genzyme-corp/increase-decrease-in-inventories https://stock.noler.com/us/stock/genzyme-corp/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/genzyme-corp/incremental-common-shares-attributable-to-contingently-issuable-shares https://stock.noler.com/us/stock/genzyme-corp/incremental-common-shares-attributable-to-conversion-of-debt-securities https://stock.noler.com/us/stock/genzyme-corp/insider-transactions-stock-options https://stock.noler.com/us/stock/genzyme-corp/insider-transactions-stock-units https://stock.noler.com/us/stock/genzyme-corp/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/genzyme-corp/interest-costs-capitalized https://stock.noler.com/us/stock/genzyme-corp/interest-expense https://stock.noler.com/us/stock/genzyme-corp/interest-on-convertible-debt-net-of-tax https://stock.noler.com/us/stock/genzyme-corp/interest-paid-net https://stock.noler.com/us/stock/genzyme-corp/inventory https://stock.noler.com/us/stock/genzyme-corp/inventory-finished-goods-net-of-reserves https://stock.noler.com/us/stock/genzyme-corp/inventory-raw-materials-net-of-reserves https://stock.noler.com/us/stock/genzyme-corp/inventory-work-in-process-net-of-reserves https://stock.noler.com/us/stock/genzyme-corp/inventory-write-down https://stock.noler.com/us/stock/genzyme-corp/investing-cash-flow https://stock.noler.com/us/stock/genzyme-corp/investment-income-net https://stock.noler.com/us/stock/genzyme-corp/investments-in-affiliates-subsidiaries-associates-and-joint-ventures https://stock.noler.com/us/stock/genzyme-corp/lease-and-rental-expense https://stock.noler.com/us/stock/genzyme-corp/leasehold-improvements-gross https://stock.noler.com/us/stock/genzyme-corp/liabilities-of-disposal-group-including-discontinued-operation-current https://stock.noler.com/us/stock/genzyme-corp/liabilities-of-disposal-group-including-discontinued-operation-noncurrent https://stock.noler.com/us/stock/genzyme-corp/long-term-debt-and-capital-lease-obligations https://stock.noler.com/us/stock/genzyme-corp/long-term-debt-and-capital-lease-obligations-current https://stock.noler.com/us/stock/genzyme-corp/long-term-purchase-commitment-amount https://stock.noler.com/us/stock/genzyme-corp/machinery-and-equipment-gross https://stock.noler.com/us/stock/genzyme-corp/marketable-securities-equity-securities https://stock.noler.com/us/stock/genzyme-corp/net-change-in-cash https://stock.noler.com/us/stock/genzyme-corp/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/genzyme-corp/notional-amount-of-foreign-currency-non-hedging-derivatives https://stock.noler.com/us/stock/genzyme-corp/oci-available-for-sale-adjustment-net-of-tax-change https://stock.noler.com/us/stock/genzyme-corp/oci-available-for-sale-tax https://stock.noler.com/us/stock/genzyme-corp/oci-defined-benefit-plans-adjustment-net-of-tax-change https://stock.noler.com/us/stock/genzyme-corp/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax-change https://stock.noler.com/us/stock/genzyme-corp/oci-minimum-pension-liability-net-adjustment-net-of-tax https://stock.noler.com/us/stock/genzyme-corp/oci-net-of-tax-change https://stock.noler.com/us/stock/genzyme-corp/oci-securities-sale-reclassification-net-of-tax https://stock.noler.com/us/stock/genzyme-corp/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/genzyme-corp/operating-cash-flow https://stock.noler.com/us/stock/genzyme-corp/operating-income https://stock.noler.com/us/stock/genzyme-corp/operating-lease-payments-due-current https://stock.noler.com/us/stock/genzyme-corp/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/genzyme-corp/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/genzyme-corp/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/genzyme-corp/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/genzyme-corp/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/genzyme-corp/other-accrued-liabilities-current https://stock.noler.com/us/stock/genzyme-corp/other-assets-fair-value-disclosure https://stock.noler.com/us/stock/genzyme-corp/other-current-assets https://stock.noler.com/us/stock/genzyme-corp/other-income https://stock.noler.com/us/stock/genzyme-corp/other-noncurrent-assets https://stock.noler.com/us/stock/genzyme-corp/other-noncurrent-liabilities https://stock.noler.com/us/stock/genzyme-corp/other-nonoperating-income-expense https://stock.noler.com/us/stock/genzyme-corp/other-restructuring-costs https://stock.noler.com/us/stock/genzyme-corp/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/genzyme-corp/paid-in-capital-tax-effect-from-share-based-compensation https://stock.noler.com/us/stock/genzyme-corp/patents-active https://stock.noler.com/us/stock/genzyme-corp/patents-pending https://stock.noler.com/us/stock/genzyme-corp/patents-rejected https://stock.noler.com/us/stock/genzyme-corp/payments-for-proceeds-from-other-investing-activities https://stock.noler.com/us/stock/genzyme-corp/payments-to-acquire-available-for-sale-debt https://stock.noler.com/us/stock/genzyme-corp/payments-to-acquire-available-for-sale-equity https://stock.noler.com/us/stock/genzyme-corp/payments-to-acquire-equity-method-investments https://stock.noler.com/us/stock/genzyme-corp/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/genzyme-corp/preferred-shares-facts https://stock.noler.com/us/stock/genzyme-corp/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/genzyme-corp/preferred-stock-shares-authorized https://stock.noler.com/us/stock/genzyme-corp/preferred-stock-shares-issued https://stock.noler.com/us/stock/genzyme-corp/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/genzyme-corp/preferred-stock-value https://stock.noler.com/us/stock/genzyme-corp/pretax-income-domestic https://stock.noler.com/us/stock/genzyme-corp/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-collaborators https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-collection-of-notes-receivable https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-divestiture-of-businesses https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-issuance-of-secured-debt https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-issuance-of-senior-long-term-debt https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans-including-stock-options https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-payments-for-other-financing-activities https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-repayments-of-bank-overdrafts https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-repayments-of-long-term-debt-and-capital-securities https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-sale-of-available-for-sale-debt https://stock.noler.com/us/stock/genzyme-corp/proceeds-from-sale-of-available-for-sale-equity https://stock.noler.com/us/stock/genzyme-corp/profit-loss https://stock.noler.com/us/stock/genzyme-corp/property-plant-and-equipment-gross https://stock.noler.com/us/stock/genzyme-corp/property-plant-and-equipment-useful-life-maximum https://stock.noler.com/us/stock/genzyme-corp/property-plant-equipment https://stock.noler.com/us/stock/genzyme-corp/provision-for-doubtful-accounts https://stock.noler.com/us/stock/genzyme-corp/public-float https://stock.noler.com/us/stock/genzyme-corp/research-and-development https://stock.noler.com/us/stock/genzyme-corp/research-and-development-expense-excluding-acquired-in-process-cost https://stock.noler.com/us/stock/genzyme-corp/research-and-development-in-process https://stock.noler.com/us/stock/genzyme-corp/restructuring-charges https://stock.noler.com/us/stock/genzyme-corp/restructuring-reserve https://stock.noler.com/us/stock/genzyme-corp/restructuring-reserve-period-expense https://stock.noler.com/us/stock/genzyme-corp/restructuring-reserve-settled-with-cash https://stock.noler.com/us/stock/genzyme-corp/restructuring-reserve-translation-adjustment https://stock.noler.com/us/stock/genzyme-corp/retained-earnings https://stock.noler.com/us/stock/genzyme-corp/revenue https://stock.noler.com/us/stock/genzyme-corp/sales-revenue-goods-net https://stock.noler.com/us/stock/genzyme-corp/sales-revenue-services-net https://stock.noler.com/us/stock/genzyme-corp/sec-comment-letters-corresp https://stock.noler.com/us/stock/genzyme-corp/sec-comment-letters-upload https://stock.noler.com/us/stock/genzyme-corp/sec-filings-10-c https://stock.noler.com/us/stock/genzyme-corp/sec-filings-10-k https://stock.noler.com/us/stock/genzyme-corp/sec-filings-10-k405 https://stock.noler.com/us/stock/genzyme-corp/sec-filings-10-q https://stock.noler.com/us/stock/genzyme-corp/sec-filings-11-k https://stock.noler.com/us/stock/genzyme-corp/sec-filings-15-12g https://stock.noler.com/us/stock/genzyme-corp/sec-filings-15-15d https://stock.noler.com/us/stock/genzyme-corp/sec-filings-25-nse https://stock.noler.com/us/stock/genzyme-corp/sec-filings-425 https://stock.noler.com/us/stock/genzyme-corp/sec-filings-8-a12g https://stock.noler.com/us/stock/genzyme-corp/sec-filings-8-b12g https://stock.noler.com/us/stock/genzyme-corp/sec-filings-8-k https://stock.noler.com/us/stock/genzyme-corp/sec-filings-ars https://stock.noler.com/us/stock/genzyme-corp/sec-filings-ct-order https://stock.noler.com/us/stock/genzyme-corp/sec-filings-def-14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-defa14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-defc14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-defs14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-dfan14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-no-act https://stock.noler.com/us/stock/genzyme-corp/sec-filings-pre-14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-prec14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-pren14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-prer14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-prrn14a https://stock.noler.com/us/stock/genzyme-corp/sec-filings-s-4 https://stock.noler.com/us/stock/genzyme-corp/sec-filings-sc-13e3 https://stock.noler.com/us/stock/genzyme-corp/sec-filings-sc-14d1 https://stock.noler.com/us/stock/genzyme-corp/sec-filings-sc-14d9 https://stock.noler.com/us/stock/genzyme-corp/sec-filings-sc-to-c https://stock.noler.com/us/stock/genzyme-corp/sec-filings-sc-to-t https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-424a https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-424b2 https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-424b3 https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-424b4 https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-424b5 https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-effect https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-rw https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/genzyme-corp/secondary-offerings-form-s-8-pos https://stock.noler.com/us/stock/genzyme-corp/segment-reporting-information-depreciation-depletion-and-amortization-expense https://stock.noler.com/us/stock/genzyme-corp/segment-reporting-segment-revenue https://stock.noler.com/us/stock/genzyme-corp/severance-costs https://stock.noler.com/us/stock/genzyme-corp/sga-expense https://stock.noler.com/us/stock/genzyme-corp/shares-authorized https://stock.noler.com/us/stock/genzyme-corp/stock-award-rsu-nonvested-number https://stock.noler.com/us/stock/genzyme-corp/stock-based-compensation https://stock.noler.com/us/stock/genzyme-corp/stock-compensation-allocation-of-recognized-period-costs-capitalized-amount https://stock.noler.com/us/stock/genzyme-corp/stock-compensation-tax-benefit-realized-from-exercise-of-stock-options https://stock.noler.com/us/stock/genzyme-corp/stock-compensation-unrecognized-costs https://stock.noler.com/us/stock/genzyme-corp/stock-compensation-unrecognized-costs-recognition-period https://stock.noler.com/us/stock/genzyme-corp/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/genzyme-corp/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/genzyme-corp/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/genzyme-corp/stock-options-exercisable-number https://stock.noler.com/us/stock/genzyme-corp/stock-options-exercisable-remaining-term https://stock.noler.com/us/stock/genzyme-corp/stock-options-exercises-in-period https://stock.noler.com/us/stock/genzyme-corp/stock-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/genzyme-corp/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/genzyme-corp/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/genzyme-corp/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/genzyme-corp/stock-options-grants-in-period https://stock.noler.com/us/stock/genzyme-corp/stock-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/genzyme-corp/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/genzyme-corp/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/genzyme-corp/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/genzyme-corp/stock-options-outstanding-number https://stock.noler.com/us/stock/genzyme-corp/stock-options-outstanding-remaining-term https://stock.noler.com/us/stock/genzyme-corp/stock-options-vested-and-expected-to-vest-exercisable-aggregate-intrinsic-value https://stock.noler.com/us/stock/genzyme-corp/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/genzyme-corp/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/genzyme-corp/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/genzyme-corp/stock-options-vested-and-expected-to-vest-outstanding-remaining-term https://stock.noler.com/us/stock/genzyme-corp/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/genzyme-corp/stockholders-equity-other https://stock.noler.com/us/stock/genzyme-corp/tax-benefit-from-stock-options-exercised https://stock.noler.com/us/stock/genzyme-corp/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/genzyme-corp/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/genzyme-corp/tax-rate-reconciliation-nondeductible-expense-charitable-contributions https://stock.noler.com/us/stock/genzyme-corp/tax-rate-reconciliation-nondeductible-expense-meals-and-entertainment https://stock.noler.com/us/stock/genzyme-corp/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/genzyme-corp/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/genzyme-corp/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/genzyme-corp/tax-rate-reconciliation-tax-credits https://stock.noler.com/us/stock/genzyme-corp/tax-rate-reconciliation-tax-settlements https://stock.noler.com/us/stock/genzyme-corp/tax-reconciliation-tax-credits https://stock.noler.com/us/stock/genzyme-corp/tax-reconciliation-tax-settlements https://stock.noler.com/us/stock/genzyme-corp/total-assets https://stock.noler.com/us/stock/genzyme-corp/total-liabilities https://stock.noler.com/us/stock/genzyme-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/genzyme-corp/unamortized-debt-issuance-expense https://stock.noler.com/us/stock/genzyme-corp/unrecognized-tax-benefits https://stock.noler.com/us/stock/genzyme-corp/utb-decrease-from-prior-year-positions https://stock.noler.com/us/stock/genzyme-corp/utb-increase-from-current-year-positions https://stock.noler.com/us/stock/genzyme-corp/utb-increase-from-prior-year-positions https://stock.noler.com/us/stock/genzyme-corp/utb-that-would-impact-effective-tax-rate